Cargando…
Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study
OBJECTIVES: Although COVID-19 vaccines offer protection against infection and severe disease, there is limited information on the effect of vaccination on prolonged symptoms following COVID-19. Our objective was to determine differences in prevalence of prolonged symptoms 6 weeks after onset of COVI...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895915/ https://www.ncbi.nlm.nih.gov/pubmed/36731936 http://dx.doi.org/10.1136/bmjopen-2022-063141 |
_version_ | 1784881950172905472 |
---|---|
author | Mohr, Nicholas M Plumb, Ian D Harland, Kari K Pilishvili, Tamara Fleming-Dutra, Katherine E Krishnadasan, Anusha Hoth, Karin F Saydah, Sharon H Mankoff, Zachary Haran, John P Briggs-Hagen, Melissa León, Eliezer Santos Talan, David A |
author_facet | Mohr, Nicholas M Plumb, Ian D Harland, Kari K Pilishvili, Tamara Fleming-Dutra, Katherine E Krishnadasan, Anusha Hoth, Karin F Saydah, Sharon H Mankoff, Zachary Haran, John P Briggs-Hagen, Melissa León, Eliezer Santos Talan, David A |
author_sort | Mohr, Nicholas M |
collection | PubMed |
description | OBJECTIVES: Although COVID-19 vaccines offer protection against infection and severe disease, there is limited information on the effect of vaccination on prolonged symptoms following COVID-19. Our objective was to determine differences in prevalence of prolonged symptoms 6 weeks after onset of COVID-19 among healthcare personnel (HCP) by vaccination status, and to assess differences in timing of return to work. DESIGN: Cohort analysis of HCP with COVID-19 enrolled in a multicentre vaccine effectiveness study. HCP with COVID-19 between December 2020 and August 2021 were followed up 6 weeks after illness onset. SETTING: Health systems in 12 US states. PARTICIPANTS: HCP participating in a vaccine effectiveness study were eligible for inclusion if they had laboratory-confirmed symptomatic SARS-CoV-2 with mRNA vaccination (symptom onset ≥14 days after two doses) or no prior vaccination. Among 681 eligible participants, 419 (61%) completed a follow-up survey to assess symptoms reported 6 weeks after illness onset. EXPOSURES: Two doses of a COVID-19 mRNA vaccine compared with no COVID-19 vaccine. MAIN OUTCOME MEASURES: Prevalence of symptoms 6 weeks after onset of COVID-19 illness and days to return to work. RESULTS: Among 419 HCP with COVID-19, 298 (71%) reported one or more COVID-like symptoms 6 weeks after illness onset, with a lower prevalence among vaccinated participants compared with unvaccinated participants (60.6% vs 79.1%; adjusted risk ratio 0.70, 95% CI 0.58 to 0.84). Following their illness, vaccinated HCP returned to work a median 2.0 days (95% CI 1.0 to 3.0) sooner than unvaccinated HCP (adjusted HR 1.37, 95% CI 1.04 to 1.79). CONCLUSIONS: Receipt of two doses of a COVID-19 mRNA vaccine among HCP with COVID-19 illness was associated with decreased prevalence of COVID-like symptoms at 6 weeks and earlier return to work. |
format | Online Article Text |
id | pubmed-9895915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-98959152023-02-03 Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study Mohr, Nicholas M Plumb, Ian D Harland, Kari K Pilishvili, Tamara Fleming-Dutra, Katherine E Krishnadasan, Anusha Hoth, Karin F Saydah, Sharon H Mankoff, Zachary Haran, John P Briggs-Hagen, Melissa León, Eliezer Santos Talan, David A BMJ Open Infectious Diseases OBJECTIVES: Although COVID-19 vaccines offer protection against infection and severe disease, there is limited information on the effect of vaccination on prolonged symptoms following COVID-19. Our objective was to determine differences in prevalence of prolonged symptoms 6 weeks after onset of COVID-19 among healthcare personnel (HCP) by vaccination status, and to assess differences in timing of return to work. DESIGN: Cohort analysis of HCP with COVID-19 enrolled in a multicentre vaccine effectiveness study. HCP with COVID-19 between December 2020 and August 2021 were followed up 6 weeks after illness onset. SETTING: Health systems in 12 US states. PARTICIPANTS: HCP participating in a vaccine effectiveness study were eligible for inclusion if they had laboratory-confirmed symptomatic SARS-CoV-2 with mRNA vaccination (symptom onset ≥14 days after two doses) or no prior vaccination. Among 681 eligible participants, 419 (61%) completed a follow-up survey to assess symptoms reported 6 weeks after illness onset. EXPOSURES: Two doses of a COVID-19 mRNA vaccine compared with no COVID-19 vaccine. MAIN OUTCOME MEASURES: Prevalence of symptoms 6 weeks after onset of COVID-19 illness and days to return to work. RESULTS: Among 419 HCP with COVID-19, 298 (71%) reported one or more COVID-like symptoms 6 weeks after illness onset, with a lower prevalence among vaccinated participants compared with unvaccinated participants (60.6% vs 79.1%; adjusted risk ratio 0.70, 95% CI 0.58 to 0.84). Following their illness, vaccinated HCP returned to work a median 2.0 days (95% CI 1.0 to 3.0) sooner than unvaccinated HCP (adjusted HR 1.37, 95% CI 1.04 to 1.79). CONCLUSIONS: Receipt of two doses of a COVID-19 mRNA vaccine among HCP with COVID-19 illness was associated with decreased prevalence of COVID-like symptoms at 6 weeks and earlier return to work. BMJ Publishing Group 2023-02-02 /pmc/articles/PMC9895915/ /pubmed/36731936 http://dx.doi.org/10.1136/bmjopen-2022-063141 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Mohr, Nicholas M Plumb, Ian D Harland, Kari K Pilishvili, Tamara Fleming-Dutra, Katherine E Krishnadasan, Anusha Hoth, Karin F Saydah, Sharon H Mankoff, Zachary Haran, John P Briggs-Hagen, Melissa León, Eliezer Santos Talan, David A Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title | Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title_full | Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title_fullStr | Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title_full_unstemmed | Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title_short | Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study |
title_sort | presence of symptoms 6 weeks after covid-19 among vaccinated and unvaccinated us healthcare personnel: a prospective cohort study |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895915/ https://www.ncbi.nlm.nih.gov/pubmed/36731936 http://dx.doi.org/10.1136/bmjopen-2022-063141 |
work_keys_str_mv | AT mohrnicholasm presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT plumbiand presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT harlandkarik presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT pilishvilitamara presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT flemingdutrakatherinee presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT krishnadasananusha presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT hothkarinf presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT saydahsharonh presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT mankoffzachary presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT haranjohnp presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT briggshagenmelissa presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT leoneliezersantos presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT talandavida presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy AT presenceofsymptoms6weeksaftercovid19amongvaccinatedandunvaccinatedushealthcarepersonnelaprospectivecohortstudy |